Hypertrophic Cardiomyopathy: State of the Art

IF 6.9 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Mayo Clinic proceedings Pub Date : 2025-03-01 DOI:10.1016/j.mayocp.2024.07.013

Steve R. Ommen MD , Rick A. Nishimura MD , Hartzell V. Schaff MD , Joseph A. Dearani MD

{"title":"Hypertrophic Cardiomyopathy: State of the Art","authors":"Steve R. Ommen MD , Rick A. Nishimura MD , Hartzell V. Schaff MD , Joseph A. Dearani MD","doi":"10.1016/j.mayocp.2024.07.013","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. Patients with HCM who are treated according to modern guidelines can reasonably be expected to have normal longevity and good quality of life. Nevertheless, effort intolerance, heart failure, arrhythmias, and sudden cardiac death can occur in some patients. Comprehensive and longitudinal assessment with echocardiography, ambulatory electrocardiography, stress testing, and in some cases cardiac magnetic resonance imaging helps guide therapy. Symptomatic patients can be treated with medications including a new class, cardiac myosin inhibitors, developed specifically to treat the cellular pathophysiologic mechanism of HCM. For patients whose symptoms do not respond to medical therapy or in whom medical therapy is not desired, invasive options to relieve symptoms, when performed at expert centers, have robust data for successful outcomes. The goal of management is to encourage and help patients with HCM lead an active, healthy lifestyle that includes regular exercise similar to activity recommendations for the general public.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Pages 557-566"},"PeriodicalIF":6.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mayo Clinic proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0025619624003574","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. Patients with HCM who are treated according to modern guidelines can reasonably be expected to have normal longevity and good quality of life. Nevertheless, effort intolerance, heart failure, arrhythmias, and sudden cardiac death can occur in some patients. Comprehensive and longitudinal assessment with echocardiography, ambulatory electrocardiography, stress testing, and in some cases cardiac magnetic resonance imaging helps guide therapy. Symptomatic patients can be treated with medications including a new class, cardiac myosin inhibitors, developed specifically to treat the cellular pathophysiologic mechanism of HCM. For patients whose symptoms do not respond to medical therapy or in whom medical therapy is not desired, invasive options to relieve symptoms, when performed at expert centers, have robust data for successful outcomes. The goal of management is to encourage and help patients with HCM lead an active, healthy lifestyle that includes regular exercise similar to activity recommendations for the general public.

查看原文本刊更多论文

肥厚性心肌病：最新进展

肥厚性心肌病（HCM）是最常见的遗传性心肌病。根据现代指南治疗的HCM患者可以合理地期望有正常的寿命和良好的生活质量。然而，一些患者可能出现心力不耐受、心力衰竭、心律失常和心源性猝死。综合和纵向评估超声心动图，动态心电图，压力测试，并在某些情况下心脏磁共振成像有助于指导治疗。有症状的患者可以用药物治疗，包括一类新的药物，心脏肌球蛋白抑制剂，专门用于治疗HCM的细胞病理生理机制。对于症状对药物治疗无效或不需要药物治疗的患者，在专家中心进行侵入性治疗以缓解症状，可以获得成功结果的可靠数据。管理的目标是鼓励和帮助HCM患者过上积极健康的生活方式，包括定期锻炼，类似于一般公众的活动建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mayo Clinic proceedings 医学-医学：内科

CiteScore

16.80

自引率

1.10%

发文量

383

审稿时长

37 days

期刊介绍： Mayo Clinic Proceedings is a premier peer-reviewed clinical journal in general medicine. Sponsored by Mayo Clinic, it is one of the most widely read and highly cited scientific publications for physicians. Since 1926, Mayo Clinic Proceedings has continuously published articles that focus on clinical medicine and support the professional and educational needs of its readers. The journal welcomes submissions from authors worldwide and includes Nobel-prize-winning research in its content. With an Impact Factor of 8.9, Mayo Clinic Proceedings is ranked #20 out of 167 journals in the Medicine, General and Internal category, placing it in the top 12% of these journals. It invites manuscripts on clinical and laboratory medicine, health care policy and economics, medical education and ethics, and related topics.